Teva Pharma (TEVA) Tops Q4 EPS by 2c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Capital Reiterates Outperform Rating and $42 PT on Teva Pharmaceuticals (TEVA) Following 4Q Results
February 14, 2017 8:47 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Outperform rating and $42 price target on Teva Pharmaceuticals Industries (NYSE: TEVA), suggesting strategic questions remain, despite the company reporting 2016 fourth quarter results above consensus.
Stanicky comments, "TEVA reported 4Q above Street expectations and reaffirmed 2017... More
Teva Pharma (TEVA) PT Lowered to $40 at Maxim Group
February 13, 2017 1:14 PM ESTMaxim Group lowered its price target on Teva Pharma (NYSE: TEVA) to $40.00 (from $41.00) while maintaining a Hold rating following results this morning.
Analyst Gabrielle Zhou commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues... More
